CG
EGRX

Cutler Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cutler Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-803
Closed -$40K – 6240
2021
Q4 		$40K Buy
+803
New +$41.6K ﹤0.01% 2582
2019
Q2 		– Sell
-200
Closed -$10K – 4928
2019
Q1 		$10K Hold
200
– – ﹤0.01% 2517
2018
Q4 		$8K Sell
200
-200
-50% -$10.3K ﹤0.01% 2685
2018
Q3 		$27K Buy
400
+100
+33% +$7.58K ﹤0.01% 2059
2018
Q2 		$22K Sell
300
-100
-25% -$6.29K ﹤0.01% 2140
2018
Q1 		$21K Buy
400
+300
+300% +$17.4K ﹤0.01% 2266
2017
Q4 		$5K Sell
100
-3,261
-97% -$181K ﹤0.01% 3697
2017
Q3 		$200K Buy
3,361
+1,579
+89% +$95.5K 0.01% 1180
2017
Q2 		$140K Buy
1,782
+1,682
+1,682% +$138K 0.01% 1578
2017
Q1 		$8K Sell
100
-1,944
-95% -$145K ﹤0.01% 4317
2016
Q4 		$162K Buy
+2,044
New +$148K 0.01% 1478
2016
Q3 		– Sell
-2,849
Closed -$158K – 7531
2016
Q2 		$110K Buy
2,849
+1,547
+119% +$64.4K 0.01% 1606
2016
Q1 		$52K Sell
1,302
-1,367
-51% -$86.7K ﹤0.01% 2301
2015
Q4 		$236K Buy
+2,669
New +$211K 0.01% 1056

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Cutler Group's EGRX Position: Q1 2022 in Review

Cutler Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 803 shares — an estimated $40K sold.

Cutler Group first reported a position in EGRX in Q4 2015 and held it in 14 quarters. The position peaked at $236K in Q4 2015. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • Cutler Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 803 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $40K.
  • Cutler Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 14 quarters.
  • Cutler Group's Eagle Pharmaceuticals, Inc. position peaked at $236K in Q4 2015.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.